ArticleBMC infectious diseases2025
Comparative genomic and phenotypic analysis of Escherichia coli ST1193 and ST131 from urinary and bloodstream infections: insights into resistance, virulence, and divergent strategies.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Whole-genome characterisation of high-risk ST131 and the emerging ST1193 UPEC lineages in Romanian patients with recurrent urinary tract infections.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe global dissemination of multidrug-resistant (MDR) Escherichia coli (E. coli) clones, particularly the pandemic ST131 and the emerging ST1193, poses a serious public health threat. While ST131 is well-studied, the factors enabling ST1193’s rapid dissemination across both urinary and bloodstream infection niches remain unclear.
methodsWe compared 48 urinary (UPEC) and bloodstream (BPEC) E. coli isolates of ST1193 (n = 24) and ST131 (n = 24) from Shanghai, using integrated phenotypic-genotypic analysis, including antimicrobial susceptibility, whole-genome sequencing (WGS), hemolysin assays, Galleria mellonella larval infection model.
resultsBoth lineages exhibited high rates of multidrug resistance with strongly genotype-phenotype concordance. Key contrasts emerged: ST1193-BPEC showed significantly higher resistance to trimethoprim/sulfamethoxazole than ST131-BPEC (p < 0.05), while ST131 overall demonstrated greater resistance to cefotaxime/cefazolin and a higher ESBL prevalence (ST131 83.33% vs. ST1193 50.00%, p < 0.05). All ST1193 isolates were resistant to fluoroquinolones but remained susceptible to carbapenems and ceftazidime-avibactam. Genomic analysis revealed striking conservation in ST1193, with near-uniform presence of fimH64 (23/24), K1 capsule (100%), and O75:H5 serotype (91.7%), along with unique virulence genes (vat, neuABCD, hcp2, kpsT, espL1). In contrast, ST131 displayed heterogeneity in fimH alleles (predominantly fimH30), K5 capsule (95.8%), and serotypes (O25:H4/O16:H5). Hemolysin production was exclusive to ST131 isolates (5/24). Virulence assays revealed divergent patterns: ST131-UPEC isolates showed significantly higher lethality in G. mellonella than ST131-BPEC (p = 0.024), whereas ST1193 virulence remained consistent across niches (UPEC vs. BPEC: p = 0.843).
conclusionsOur study confirms that ST1193 and ST131 are high-risk MDR clones employing distinct strategies—genomic conservation in ST1193 versus heterogeneity in ST131. Both exhibit substantial virulence and resistance, with fimH64 and fimH30 representing stable, lineage-specific markers. These conserved FimH variants present promising targets for future anti-adhesion therapeutics. Further mechanistic and multi-center studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.